Form 4: Axsome Therapeutics Director Exercises Stock Options, Holds Shares
SEC Form 4 Filing
Director Mark Coleman exercised stock options in Axsome Therapeutics, acquiring shares while also holding a significant indirect ownership stake.
Summary
- On January 3, 2025, Mark Coleman, a director of Axsome Therapeutics, exercised stock options to acquire 9,127 shares of common stock at a price of $9 per share.
- Following the transaction, Coleman directly owns 57,137 shares of Axsome Therapeutics.
- Coleman also indirectly owns 403,856 shares through an entity where he has voting and dispositive power.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option exercise. It doesn't inherently indicate positive or negative company performance.
Positives
- The director's exercise of stock options could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing indicates a director's activity in exercising stock options.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 11/19/2016 | Original grant date of the stock options exercised. |
| 11/19/2025 | Expiration date of the stock options exercised. |
| 01/03/2025 | Date of stock option exercise and share acquisition. |
| 01/06/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.